Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer
- 1 November 2019
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 121, 48-54
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Sanofi
- Merck
- Lilly
- Roche
- Bayer
- Janssen
- CLOVIS
- Sanofi
- Merck
- Sanofi
- Baye
- Sanofi
- JnJ
- Merck
- Astellas
- Sanofi
- Astellas
- Sanofi
- Astellas
- Janssen
- Bayer
- Cancer Genomics Netherlands
- Lilly
- Sanofi
- Philips
- Therawis
- PamGene
- Janssen
- Sanofi Genzyme
This publication has 15 references indexed in Scilit:
- Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate CancerEuropean Urology, 2018
- An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor CellsThe Journal of Molecular Diagnostics, 2018
- Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II StudyClinical Cancer Research, 2017
- Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate CancerClinical Cancer Research, 2017
- AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone AcetateJournal of Urology, 2017
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targetingProstate Cancer and Prostatic Diseases, 2016
- Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor CellsEuropean Urology, 2015
- Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agentsBritish Journal of Cancer, 2015
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004